Sort
40,608 grants matching “prostate cancer”
Washington University Molecular Imaging Center
$363,851David R Piwnica-Worms · Washington University · P50 · FY2007 · CA
Project 1: Modeling tumor evolution in mouse and organoid models
$363,795Raul Rabadan · Columbia University Health Sciences · U54 · FY2016 · CA
CLINICAL ULTRASONIC CHARACTERIZATION OF THE PROSTATE
$363,775Riverside Research Institute · R01 · FY2000 · CA
miRNA Expression Profiling
$363,768David M Brown · Ambion Diagnostics, Inc. · R44 · FY2006 · CA
Role of JAK2-PAK1 interaction in prolactin-dependent signaling
$363,750Maria Diakonova · University Of Toledo · R01 · FY2010 · DK
Therapeutic Efficacy of Flaxseed in the Treatment of Ovarian Cancer
$363,750Dale B Hales · Southern Illinois University Carbondale · R01 · FY2011 · AT
Prevention and Treatment of Impotence
$363,727Tom F Lue · University Of California, San Francisco · R37 · FY2011 · DK
Prevention and Treatment of Impotence
$363,727Tom F Lue · University Of California, San Francisco · R37 · FY2012 · DK
KALAMAZOO COMMUNITY CLINICAL ONCOLOGY PROGRAM
$363,725West Michigan Cancer Center · U10 · FY2000 · CA
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2016 · CA
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2018 · CA
Regulation of pten tumor suppressive functions by C-tail phosphorylation.
$363,713Darren Baker · Mayo Clinic Rochester · R01 · FY2019 · CA
Mechanism of non-oncogene addiction
$363,713Mohammad Azam · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · CA
UFM1 signaling in DNA damage response and cancer therapy
$363,713Zhenkun Lou · Mayo Clinic Rochester · R01 · FY2020 · CA
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2018 · CA
UFM1 signaling in DNA damage response and cancer therapy
$363,713Zhenkun Lou · Mayo Clinic Rochester · R01 · FY2021 · CA
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2021 · CA
UFM1 signaling in DNA damage response and cancer therapy
$363,713Zhenkun Lou · Mayo Clinic Rochester · R01 · FY2018 · CA
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2017 · CA
Regulation of pten tumor suppressive functions by C-tail phosphorylation.
$363,713Darren Baker · Mayo Clinic Rochester · R01 · FY2021 · CA
Mechanism and role of aberrant AR activity in castration-resistant prostate cancer
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2020 · CA
Role of CPT1A as a lysine succinyltransferase in tumorigenesis
$363,713Taro Hitosugi · Mayo Clinic Rochester · R01 · FY2020 · CA
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progression
$363,713Haojie Huang · Mayo Clinic Rochester · R01 · FY2015 · CA
Role of CPT1A as a lysine succinyltransferase in tumorigenesis
$363,713Taro Hitosugi · Mayo Clinic Rochester · R01 · FY2018 · CA
Role of CPT1A as a lysine succinyltransferase in tumorigenesis
$363,713Taro Hitosugi · Mayo Clinic Rochester · R01 · FY2021 · CA